Clinical Trial Update: Efficacy and Safety Study of Ixoberogene Soroparvovec (Ixo-vec) in Participants With Neovascular Age-related Macular Degeneration (AQUARIUS) [Phase 3]

View source ↗

Summary

Phase 3 trial AQUARIUS is evaluating the efficacy and safety of Ixo-vec (Ixoberogene soroparvovec) in neovascular/wet age-related macular degeneration; the stud…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neovascular Age-related Macular Degeneration
• Wet Age-related Macular Degeneration

Drugs mentioned

• Ixo-vec (Ixoberogene soroparvovec)

Snippet

Sponsor: Adverum Biotechnologies, Inc. | Conditions: Neovascular Age-Related Macular Degeneration (nAMD), Wet AMD | Phase 3 | Status: RECRUITING